Market Growth Driven by Increasing Drug Approvals, Advanced Technologies, Rising Chronic Disease Incidence, and Expanding Therapeutic Applica ...

The agency is considering further regulatory action after a second Duchenne patient died from acute liver failure less than two months after receiving the gene therapy.

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi.

Sarepta stock dropped again Wednesday — extending a steep dive this year — after the Food and Drug Administration announced that it's investigating the deaths of two patients who received Sarepta ...

Viking Therapeutics announced the start of Phase 3 studies involving its injectable, GLP-1/GIP-targeted obesity drug, called ...

Sarepta reports a second fatal case of acute liver failure linked to Elevidys. Analyst cuts Sarepta’s rating due to uncertain safety and future revenue potential. Get ahead of Wall Street ...

Sarepta Therapeutics (SRPT) is facing a storm of skepticism on Wall Street following safety concerns linked to its flagship gene therapy, Elevidys. Yet, despite recent downgrades and a sharp sell ...

Sarepta Therapeutics has established itself as a leader in the development of treatments for DMD, with a portfolio that includes FDA-approved exon-skipping therapies such as Exondys 51, Vyondys 53, ...

Sarepta’s consensus price target among the 25 MarketBeat-tracked analysts is around $70, implying a potential upside of more than 230%. This huge divergence likely reflects the fact that Sarepta ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...